Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity

Nephrology Dialysis Transplantation

Volumn 22, Issue 7, 2007, Pages 1963-1968

  Joy, Melanie S ^a   Hogan, Susan L ^a   Thompson, Bawana D ^a   Finn, William F ^a   Nickeleit, Volker ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclosporine; Cytochrome P450; Immunohistochemistry; Nephrotoxicity; Renal transplant recipients; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CARBAMAZEPINE; CYTOCHROME P450 3A5; DILTIAZEM; FLUCONAZOLE; FLUOXETINE; HYDROCORTISONE; PAROXETINE; PREDNISONE; SERTRALINE; TRAZODONE; VITAMIN D;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; MALE; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CALCINEURIN; CELL MEMBRANE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES, DISTAL; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; STAINING AND LABELING;

EID: 34547830270     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm133     Document Type: Article

References (35)

1. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001; 59: 1484-1490
2. Hu W, Liu Z, Shen S et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (Engl) 2003; 116: 1827-1830
3. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56: 2220-2226
4. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991; 51: 428-430
5. Nizze H, Mihatsch MJ, Zollinger HU et al. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants. Clin Nephrol 1988; 30: 248-260
6. Zietse R, Balk AH, vd Dorpel MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14: 1-5
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
8. Colvin RB, Nickeleit V. Renal Transplant Pathology. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, eds. Heptinstall's Pathology of the Kidney. Lippincott Williams & Wilkins, Philadelphia: 2006; 1349-1490
9. Goldfarb DA. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. J Urol 2003; 169: 2436-2437
10. Anjaneyulu M, Tirkey N, Chopra K. Attenuation of cyclosporine-induced renal dysfunction by catechin: Possible antioxidant mechanism. Ren Fail 2003; 25: 691-707
11. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465-476
12. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080
13. Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl 1998; 65: S11-S17
14. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin Inhibitor-Induced Nephrotoxicity and Renal Expression of P-glycoprotein. Pharmacotherapy 2005; 25: 779-789
15. Tsuruoka S, Sugimoto KI, Fujimura A, Imai M, Asano Y, Muto S. P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro. J Am Soc Nephrol 2001; 12: 177-181
16. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60: 156-166
17. Inoue K, Inazawa J, Nakagawa H et al. Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn J Hum Genet 1992; 37: 133-138
18. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134
19. Schuetz EG, Schuetz JD, Grogan WM et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992; 294: 206-214
20. Haehner BD, Gorski JC, Vandenbranden M et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52-59
21. Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-213
22. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20: 759-771
23. Mihatsch MJ, Helmchen U, Casanova P et al. Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus. Klin Woehenschr 1991; 69: 354-359
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
25. Product Information. Neoral (R), cyclosporine. In: Pharmaceuticals N, ed. East Hanover, NJ, 2001.
26. Product Information. SangCya (TM), cyclosporine. In: Corporation SM, ed. Menlo Park, CA, 1998.
27. Yee GC, Recent advances in cyclosporine pharmacokinetics. Pharmacotherapy 1991; 11: 130S-134S
28. Product Information. Prograf (R), tacrolimus. In: Fugisawa USA I, ed. Deerfield, IL, 2001.
29. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-183
30. Murray GI, McFadyen MC, Mitchell RT, Cheung YL, Kerr AC, Melvin WT. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 1999; 79: 1836-1842
31. Warrington JS, Greenblatt D J, von Moltke LL. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J Pharmacol Exp Ther 2004; 309: 720-729
32. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome p450 in chronic renal failure: Role of uremic mediators. Br J Pharmacol 2002; 137: 1039-1046
33. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-1320
34. Dreisbach AW, Japa S, Gebrekal AB et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003; 73: 475-477
35. Dowling TC, Briglia AE, Fink JC et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003; 73: 427-434